Skip to main content

Starling Oncology, Inc 8-K, filed Nov 5, 2026

Starling Oncology, Inc. (STLN)

8-K 2026-11-05 For: 2026-11-05
View Original
Added on November 05, 2026

About this 8-K

Starling Oncology, Inc filed this 8-K on November 5, 2026.

Starling Oncology reported third-quarter revenue of $169.8 million, up 24.3% year over year, and Adjusted EBITDA of positive $3.4 million. It updated fiscal-year 2026 revenue guidance to $650 to $660 million and Adjusted EBITDA guidance to $4 to $6 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits